Deals of the Week: Options Abound As Forest Keeps Its Eyes On A Prize-Winner
Reflecting a long trend, three of this past week’s deals include option arrangements, including one with a new twist. Also, a rare disease partnership between Shire and Atlas Venture finally leads to a deal and Takeda continues building its vaccines business.
You may also be interested in...
Since fixing its eyes on China, Amgen has been scouting the country for deals. Now the first result is in, a JV with local industry darling Beta Pharma to commercialize Vectibix in China.
Cell Therapeutics licenses Phase III pacritinib from Singapore’s S*BIO about a year after Onyx declined an option on the myelofibrosis candidate.
Collaboration will create start-up biotechs to advance promising research in orphan indications, but the companies will not take a “cookie cutter” approach to structure or evolution.